WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
SJIF Impact Factor 8.084
Volume 11, Issue 2, 418-454. Review Article ISSN 2277– 7105

RECENT UPDATES IN THE TREATMENT OF OVERACTIVE BLADDER SYNDROME

***[1]Dr. Asif Rasheed, [2]Erram Fatima Khan and [3]Maryam Sadiq**

*[1]Professor and HOD- Department of Pharmacology, Deccan School of Pharmacy, India.

[2,3]Department of Pharmacology, Deccan School of Pharmacy.

Article Received on
01 December 2021,

Revised on 22 Dec. 2021,
Accepted on 12 Jan. 2022

DOI: 10.20959/wjpr20222-22842

***Corresponding Author**
Dr. Asif Rasheed
Professor and HOD-Department of Pharmacology, Deccan School of Pharmacy, India.

ABSTRACT

Overactive bladder is symptom- based condition defined as a syndrome of urinary urgency, with or without urgency incontinence, usually with urinary frequency (voiding eight or more times in a 24-hour period) and nocturia (awakening two or more times at night to void) in the absence of infection or other obvious pathologic features. Overactive bladder syndrome is now classified as a symptom syndrome suggestive of lower urinary tract dysfunction by the International Continence Society (ICS). OAB is commonly called as "detrusor overactivity/ unstable bladder/detrusor hyperreflexia". OAB has an impact on everyday activities and social functions like employment, travel, physical activity, sleep, and sexual function.

KEYWORDS: Bladder, Detrusor malfunction, Urgency, Incontinence, Diabetes, Hyperlipidemia, Bladder outlet obstruction, Inflammation.

INTRODUCTION

Overactive bladder (OAB) is symptom- based[1] condition defined as a syndrome of urinary urgency, with or without urgency incontinence, usually with urinary frequency (voiding eight or more times in a 24-hour period)[3,4] and nocturia (awakening two or more times at night to void)[3,4,5] in the absence of infection or other obvious pathologic features.[1-5] Overactive bladder syndrome is now classified as a symptom syndrome suggestive of lower urinary tract dysfunction by the International Continence Society (ICS).[6] OAB is commonly called as "detrusor overactivity/unstable bladder/detrusor hyperreflexia".[7] OAB has an impact on everyday activities and social functions like employment, travel, physical activity, sleaep, and sexual function.[8,9] Nocturia is associated with sleep disruption, which decreases the quality

of life.[14-17] In the absence of a urinary tract infection, metabolic disturbances (affecting urination), or urinary stressed incontinence (generated by effort or overexertion). Only a third of people with OAB experience urge incontinence, often known as wet OAB. This is not to be associated with incontinence caused by the urethra and pelvic floor failing to tolerate gastric pressure, which is typically not accompanied with "urgency." Mixed urinary symptoms are a diagnosis granted to individuals who have both OAB and urinary stress incontinence symptoms.[8,9,10]

Overactive bladder has an unknown etiology.[13] Obesity, coffee consumption, and constipation[12] are all risk factors. Diabetes that is poorly managed, low functional mobility, and chronic pelvic discomfort can all exacerbate the symptoms.[13] People typically suffer symptoms for a long period before seeking therapy, and caregivers are sometimes the first one to notice the condition. Other disorders such as urinary tract infections or neurological illnesses must be ruled out before a diagnosis can be made based on a person's signs and symptoms.[11,13] During each urination, only a little amount of pee is passed. Other than hyperactive bladder, pain when peeing indicates that there is a problem.[13]

EPIDEMIOLOGY

The prevalence of OAB also varies by race/ethnicity for both men and women. Based on data from the EpiLUTS study, the prevalence of OAB is 33.3 % in AfricanAmerican (AA) men, 28.0 % in Hispanic men, 27.0 % in Asian men, and 26.3 % in White men. OAB was reported by 45.9 % of AA, 43.4 % of White, 42.0 % of Hispanic, and 26.6 % of Asian women.[20] Data from the OAB-POLL study on racial prevalence are slightly different, even though methods were similar.[15] OAB prevalence was higher for AA (20.2 %) men than Hispanic (18.1 %) or white men (14.6 %); and for women, OAB was prevalent in 32.6 % of AA, 29.0 % of Hispanic, and 29.4 % white women. NHANES data on UI supports that AA women report the highest prevalence of urge-UI (11.0 %) over white and Mexican-American women (7.5 and 7.5 %, respectively)[19]

Urinary incontinence (UI) has also been studied extensively, and the prevalence rates vary widely. The EPIC study reported that women had a much higher rate of any UI (urge, mixed, stress, and other) than men (13.1% vs 5.4%). The prevalence of OAB in Asian men is high and more common in older patients. The treatment rate for the symptoms was much lower than in western countries, suggesting a need for better education of patients and more research for effectively managing the OAB. Two recently printed international prevalence

studies from Europe and Asia show totally different prevalence values [Europe: 15.6% (men), 17.4% (women); Asia: 53.1% (women)], which can result to method differences. each studies report a rise of OAB prevalence corresponding with age. The accumulative incidence of OAB is rising quicker in aging males than in aging females. 2-thirds of the European and quartern of the Asian people tormented by OAB complained regarding impaired quality of life, however solely 60% of the European and 21% of the Asian sufferers have talked to a doctor or wanted treatment. One out of 4 patients visiting their health care skilled for OAB symptoms is presently beneath medication. To avoid high treatment prices and facet effects, pharmacotherapy (e.g., antimuscarinics) ought to solely lean once careful diagnostic evaluation.[23]

ETIOLOGY

The etiology of OAB contains animal tissue and non-neurogenic detrusor upset similarly as detrusor hypersensitivity. Animal tissue detrusor hyperactivity could also be caused by meagerly animal tissue inhibition, chronic neuropathies, and neural structure lesions, whereas bladder aging, bladder outlet obstruction, and chronic bladder irritation (UTI, stones, tumors) are attainable causes for nonneurogenic detrusor hyperactivity.

The main factors of OAB are primarily of three types:

1) Neurogenic – Damaged central inhibitory pathways (de Groat WC.).

2) Myogenic- variations in the detrusor muscles,[24] resulting in myogenic contractions[24-26] and its increased sensitivity to neurotransmitters.[27]

3) Urotheliogenic

Since most medical specialty surveys specialize in enuresis while not considering urgency frequency without incontinence, epidemiologic knowledge regarding

OAB are rare. Most common causes of OAB are

- Weak pelvic muscles which are majorly caused in females during pregnancy or childbirth
- Nerve damages, where the brain sends signals to the bladder at unusual times to pee. Some psychological diseases, hernias, pelvic surgeries etc.
- Medications like the diuretics increase diuresis causing urinary frequency.
- UTI: The most common infection, which is characterized by urinary urgencies and emergencies.
- Menopause, during which the levels of estrogen reduces.[23-28]

- Improper bladder emptying
- Drinking too much fluids.[29]
- Pelvic prolapse
- Prostatic hypertrophy[30]
- Age, as age ascends the mind loses alertness causing unknown urinary leak[31]
- Constipation
- Bladder obstructions
- Diabetes[32]
- Interstitial cystitis[34]

SIGNS AND SYMPTOMS:

- Urgency
- Frequency >8 times a day
- Nocturia
- Urinary Incontinence[28,29]

DIAGNOSIS

The patients must not feel shy to consult a doctor for the issue of OAB. The tests which can be done for evaluation are CUE, Neurological exams for focusing ability which may recognize abnormal reflexes, urinalysis, urine culture, rectal exams, pelvic exams.[33] Some other useful tests include Urine cytology, PVR (Post Void Residue), Ultrasound, Urodynamic measurements to measure detrusor muscle activity.[34] Tests for bladder functions including the volume of urine left in the bladder, Ultrasound which measures the thickness of the bladder wall, detecting the rate of flow of urine by using uroflow meter, Bladder pressure test by using Cystometry.[32]

PATHOPHYSIOLOGY

The pathophysiology can be explained by the three major causes which are, Myogenic, Neurogenic and Urotheliogenic.

1) Myogenic Cause[35-39]

a]



b] Partial denevation of detrusor

↓

Supersensitivity of detrusor to neurotransmitters

↓

Augmentation of response.

2) Neurogenic Cause[42]

Damage to the central inhibitory path in brain and spinal cord.

{Or}

Sensitization of peripheral afferent terminals in bladder

↓

Suprapontine inhibition

↓

Damage to axonal pathay in spinal cords



A study by Kessler et al. described the involvement of thalamus, as an important part playing a regulatory role in the lower urinary tract functioning. The study also suggested that deep brain thalamic stimulation leads to "urgency".[43] A recent study which involved brain imaging proved that a substantial network of brain controls the bladder and any dysfunction in former may cause "incontinence".[44] Any alterations in the Nonadrenergic Noncholinergic (NANC) transmission also leads to OAB

In a study which aimed to detect purinergic component of nerve mediated detrusor muscle contractions, reported the occurrence of purinergic component upto 50% in OAB specimens.[45]

De Laet et al. suggested that oxybutynin may influence bladder sensory nerves directly or indirectly, inhibiting the afferent part of the micturition reflex, using a rat model.[47] Another study found that the β_3-AR agonist CL316,243 can inhibit mechanosensitive A delta-fibers but not C-fibers of primary bladder afferents in rats. CL316,243, a β_3-AR agonist, can also reduce PGE(2)-induced C-fiber hyperactivity.[48]

4,5-dichloro-1,3-diethyl-1,3-dihydro-benzoimidazol-2-one (NS4591) is the new positive modulator of calcium-activated K_+ channels, which has proved to be effective in OAB. In the primary afferent neurons of the acutely dissociated bladder, NS4591activate small conductance K_+ channels.[49]

3. Urotheliogenic cause

According to mounting evidence, the urothelium is not only a passive barrier, but also a responsive structure capable of detecting temperature, mechanical, and chemical stimuli. The excitability of afferent neurons and the contractility of the detrusor muscle may be affected by transmitters generated by the urothelium.[50,51] The absence of the urothelium may result in an increase in the detrusor's spontaneous activity.[53] Chronic urothelial damage causes an increase in urine frequency and a decrease in voiding volume.[53] As a result, the urothelium plays a significant role in the pathogenesis of OAB.

Urothelial cells produce ion channels that are comparable to stretch activated (mechanosensitive) channels in neural tissue, and these channels may play a role in lower urinary tract mechanotransduction. The epithelial sodium channel (ENaC) has been linked to a variety of functions, including mechanical and nociceptive stimulus transduction.[54] TRPV1, a Ca2+-permeable, non-selective cation channel involved in nociception, is found in urothelial cells and is thought to be responsible for their sensitivity to vanilloid chemicals.[55] In cultivated urothelial cells, exogenous administration of capsaicin or resiniferatoxin raises intracellular calcium and causes transmitter release (NO, ATP). TRPV1 null animals had no response to intravesical chemical stimulation, demonstrating that TRPV1 is required for mediating urothelial responses. Despite the fact that only TRPV1 has been widely explored thus far, the role of additional TRP channels presents fresh targets to investigate.[56]

The urothelium synthesises and releases acetylcholine (Ach) in a way that differs significantly from neurons in terms of the molecular components of the ACh synthesis and release mechanism. As a result, pharmaceutical treatments to OAB might target urothelium

and nerves differently.[57] Chuang et al. found that solifenacin-induced detrusor overactivity was inhibited by human urine retrieved after ingesting the drug. The authors concluded that urine discharged following oral solifenacin administration may act at the urothelium, providing a targeted pharmacological advantage for the treatment of OAB.[58]

4. Some specific condition like the bladder outlet obstructions and Diabetes may also lead to OAB

Bladder outlet obstruction: It was discovered in 31–68 percent of individuals with OAB in urodynamic examinations of patients with lower urinary symptoms.[59,60] Patients without bladder outlet obstruction have a 25% chance of developing OAB, while those with bladder outlet obstruction have a 62% chance.[63-65] Persistent OAB symptoms were found in 25–31% of OAB individuals who had their prostate removed transurethrally.[59,60,62] In patients who have had a prostatectomy, however, the rate of de novo OAB has been reported to be less than 10%.[60,62]

NGF, TREK1, K+ channel, muscarinic, and purinergic receptors have all been implicated in bladder outlet obstruction-induced OAB.

Irritative symptoms have been linked to changes in afferent nerves. Nerve growth factor (NGF) is a secretory protein that is critical for peripheral nervous system development.[63,64] In a bladder outlet obstruction model in rats, previous research has revealed that NGF contributes in target organ–neuronal interactions that result in neural plasticity.[63-65] TRPV1 is expressed by urothelial cells as well as afferent neurons that form close contact with the bladder.[66] As a result, alterations in NGF and TRPV1 expression in the bladder may affect sensory signalling and persisting irritative sensations in unstable bladders after bladder outlet obstruction alleviation.[67]

TREK-1 is a molecular candidate for the stretch-dependent K(+) channel SDK, which is mechanosensitive and regulates the membrane potential of detrusor myocytes during bladder filling. TREK-1 may aid bladder wall relaxation during filling, allowing urine to pass through at low pressure.[68] The expression of TREK-1 channel protein and immunoreactivity in bladder smooth muscle was considerably reduced in bladder outlet obstructed animals, according to a study.[69] In sham operated animals, L-methioninol, a TREK-1 channel blocker, caused a substantial increase in premature contractions during the filling phase. L-methioninol, on the other hand, had no effect in blocked animals with an overactive detrusor

phenotype. These findings suggest that 6 weeks of bladder outlet obstruction exposure enhances the function of both BK β1-subunit and SK kinds of Ca 2+-activated K+ channels in the detrusor smooth muscle, resulting in a decrease in bladder contractility, which could be a compensatory mechanism to diminish bladder outletobstruction-induced OAB.[70]

One of the processes of detrusor contraction is the activation of muscarinic receptors on the detrusor. Furthermore, data suggests that urothelial cells express muscarinic receptors[71] and that urothelial/suburothelial muscarinic receptors are involved in the genesis of OAB or sensory urgency.[72,73] P2X receptors are ATP-gated ion channels that are likely made up of three protein subunits. Stretched urothelial cells release ATP[74,75] which binds to P2X3 receptors on suburothelial sensory afferents.[75,76] Intravesical ATP instillation causes OAB in conscious freely moving rats, indicating that ATP plays a role in urothelial signaling.

Muscarinic and purinergic receptors were found to be co-localized in the urothelium and muscle layer in a prior work using immunofluorescence labeling.[78] The expression of M2, M3, and P2X3 receptors was elevated in the urothelium of BOO animals, as evidenced by immunoreactivity and Western blotting. In the BOO group, M3 receptor expression was also higher in the muscular layer.[77-78] Changes in urothelium receptor expression could have a role in modulating afferent sensory responses in the urine bladder, according to these findings.[77]

Diabetes: In a model of streptozocin-induced diabetic rats, the influence of diabetes on bladder function was detected. Remodeling of the bladder wall occurs early in the course of diabetic bladder dysfunction.[79,80] Detrusor hypertrophy and mechanical property changes are caused by diabetes' diuresis and metabolic consequences, resulting in a decrease in bladder voiding efficiency. Detrusor overactivity can potentially be a result of diabetic vesical neuropathy in its early stages. Two-weekold streptozocin-induced diabetic rats showed increased expression of M2 and M3 receptors in the uroepithelium and bladder muscle layer.[81,82] Reduced bladder feeling and urodynamic detrusor underactivity are reported in individuals with classic diabetic cystopathy, which could explain why some diabetic bladder dysfunction patients have less urgency.

Metabolic syndrome: A study suggested that activation of M2,3-muscarinic receptors in the bladder was linked with DO in an animal model of metabolic syndrome caused by fructose eating.[83] Proinflammation, increased oxidative stress, mitochondrial dysfunction, an increase

in apoptosis in the detrusor muscle, and detrusor hypertrophy were among the metabolic perturbations caused by long-term fructose eating that contributed to DO and OAB symptoms.[84,85] Nobe et al. found lower Rho kinase and protein kinase activity, which weakened detrusor contractility, in a spontaneously hypertensive and hyperlipidemic rat model.[86]

Hyperlipidemia: In a chronic hyperlipidemic rabbit model, heritable hyperlipidemia has been demonstrated to result in decreased bladder capacity, diminished DO, and nerve degeneration.[86] This finding could help to explain why people with hyperlipidemia have more OAB symptoms.[83] According to Azadoi et al., ischemia bladder and DO are caused by hypercholesterolemia and atherosclerosis.[88,89] Internal iliac artery remodelling caused by hypercholesterolemia, as well as endothelial damage, are thought to have a role in the development of OAB, according to the researchers. Furthermore, elevated proinflammatory cytokines and leukotrienes may cause bladder hyperactivity by increasing smooth muscle contraction.

Detrusor muscle hypertrophy: In animal models of metabolic syndrome and diabetes, detrusor hypertrophy is another prevalent occurrence.[79,83,85] In a fructose-fed rat model, detrusor hypertrophy is linked to lower functional bladder capacity and higher urine frequency. Detrusor hypertrophy is frequently linked to poor compliance, high intravenous pressure, and DO, all of which can dramatically limit bladder blood flow.[90] Increased reactive nitrogen species and recurrent ischemia-reperfusion damage followed. Repeated DO and urine frequency cause oxidative stress by overworking the detrusor.[89] In the early phases of bladder hyperactivity, mitochondrial machinery could provide high-energy consumption. Excessive energy demand and stimulation in the long run may deplete the mitochondrial respiratory chain and weaken its energy transduction mechanism. Under such conditions, oxidatively strained mitochondria deform and become a source of reactive oxidative stress, triggering a self-destructive process in the mitochondrial respiratory system, resulting in protein degradation, detrusor malfunction, and eventually atrophy.

Inflammation: Inflammatory events in the body cause C-reactive protein (CRP) to be generated and released by the liver. The link between high serum CRP and a variety of LUTS implies that inflammation may play a role. Kupelian et al. looked at data from 1898 men and 1854 women who took part in the Boston Area Community Health study and had comprehensive CRP values.[91] They discovered that CRP levels enhanced the frequency of

OAB in both men and women. Chuang et al. also discovered that serum CRP levels were considerably higher in OAB wet patients (2.96 0.47 vs 0.93 0.27 mg/L, P 0.01) and OAB dry patients (2.96 0.47 vs 1.06 0.16 mg/L, P 0.05) when compared to controls.[92]

NGF is required throughout adulthood for the maintenance of the normal characteristics of small-sized afferent neurons with unmyelinated axons, as well as for the survival of sensory neurons during development (i.e. C-fiber afferents). NGF appears to be a peripheral mediator in a variety of inflammatory pain disorders, according to accumulating research.[93,94] NGF is a trophic factor produced from a target that is created in the bladder and taken up by sensory neurons before being retrogradely delivered to the spinal cord. Anti-NGF blocks afferent firing and causes bladder hyperactivity in mice when exogenous NGF is given intravenously.[95,98] In spontaneously hypertensive rats, overexpression of NGF in the bladder smooth muscle causes bladder hyperinnervation and hyperactive voiding behavior.[97] Stretching the urothelium can cause NGF synthesis and secretion in the bladder tissue. Urinary NGF levels that are elevated play a key function in moderating the feeling of urgency in OAB. As a result, NGF synthesis could be used as a biomarker for neuroplasticity, which is a typical mechanism involved in the development of OAB.

The bladder's prostaglandin E2 (PGE2), which is produced by bladder muscle and mucosa, has a complicated local function. PGE2 has an effect on both the normal and pathological micturition reflexes (e.g. mucosa injury and inflammatory mediators).[98] In rats and humans, intravenous injection of PGE2 promotes bladder overactivity by stimulating reflex micturition by activating capsaicin sensitive afferent neurons.[99,100]

The considerable rise of NGF and PGE2 levels in the urine of OAB patients revealed a link between inflammation and OAB symptoms in a prior investigation.[101] Urinary NGF levels were shown to be extremely low in normal controls, but considerably greater in patients with OAB, according to Liu et al..[102]

Additionally, urinary NGF levels in OAB wet patients were considerably greater than in OAB dry patients. According to the findings, increased urine NGF levels play a critical role in mediating the sensation of urgency in OAB. The increased percentage of DO in patients with OAB wet could explain the difference in NGF levels between OAB dry and OAB wet patients. Furthermore, in OAB patients who reacted to intravesical botulinum toxin A

injection or oral antimuscarinic medication, urine NGF levels were lower, but not in non-responders, and this was associated with a reduction in urgency severity.[103,104]

Eight asymptomatic control persons and 17 idiopathic OAB patients provided midstream urine samples to Tyagi et al.[105] Luminex multiplex ELISA technology (xMAP® technology, Affymetrix, Inc. Santa Clara, CA, USA) was used to test the urine for 12 chemokines, cytokines, growth factors, and soluble receptors. In comparison to controls, OAB patients' urine included a substantial increase in seven major inflammatory proteins. The presence of a high level of chemokines in the urine of OAB patients supports the conclusion that they have significant inflammation.[105] Apostolidis et al. discovered evidence of chronic inflammation in 59.1% of baseline biopsies (65.6 percent of NDO vs 50 percent of IDO, p = 0.049) in a study of 179 biopsies acquired from 79 patients, 123 (63.1 percent) from 51 NDO patients and 56 (26.9%) from 28 IDO patients. Inflammation may have a role in OAB pathophysiology, according to the findings.[106]

MANAGEMENT: Urological Society have introduced a two part therapeutic strategy: initial or first-line treatment and specialised secondary treatment. Dietary changes, bladder retraining, pelvic floor retraining with and without biofeedback, and anticholinergic medications as first-line medical treatment are all part of the core treatment.[107]

The goal of treatment is to achieve significant symptom relief, as measured by a decrease in total score on a confirmed standardised overactive bladder syndrome assessment in any of the symptoms of urgency, frequency, nocturia, and urge incontinence, while avoiding pharmacological adverse effects.[108]

NON- PHARMACOLOGICAL THERAPY

i) Life style modification:- Lowering intake of fluids,[109,110] caffeine[111], acidic foods, and alcohol, as well as weight loss and smoking cessation[110], are all potentially beneficial dietary approaches. Patients were instructed to increase or reduce their fluid consumption according to a preset hydration regimen in a randomised crossover experiment. The frequency, urgency, and nocturia of people who lowered their daily consumption by 25% improved significantly. Many individuals found it challenging to cut their oral consumption by half.[111] Caffeine's effects have been studied in observational studies as well as randomised double-blind placebo-controlled trials. Uroflowmetry and cystometry were performed before and after each participant drank water with and without coffee on two consecutive occasions in an

observational research to investigate the effects of caffeine at a level of 4.5 mg/ kg on bladder function.

Caffeine increased diuresis and a stronger need to urinate, as well as increasing the rate of urination and the volume of urine passed. According to the findings, coffee can increase urinary urgency and frequency, hence individuals with overactive bladder symptoms should limit their caffeine intake.

[112]The patients had a significant reduction in frequency and stress incontinence and improved urinary distress inventory and the urinary incontinence impact questionnaire score.[112] A questionnaire study assessing the effects of smoking status and intensity on symptoms of overactive bladder; 3000 questionnaires were sent to randomly identified people patient from the Finnish population register.[113] Smoking significantly associated with urinary urgency (most likely ratio 2.7, 95% confidence interval 1.7 to 4.2 for smokers and 1.8, 1.2 to 2.9 for former smokers compared to with non-smokers) and frequency (3.0, 1.8 to 5.0 and 1.7, 1.0 to 3.1). Smoking is not associated with nocturia or uncontrolled stress. Compared to smoking heavy, light smoking is associated with emergency risk (2.1, 1.1 to 3.9) and frequency (2.2, 1.2 to 4.3).[113] Several singles Prospective arm studies have shown that reducing fluid intake at night reduces nocturia and improves the quality of life symptom score.[114,115] However, the resulting concentrated urine can also act as a bladder irritant due to increased acidity.[116]

Behavioral therapies (e.g., bladder training, bladder-control strategies, pelvic floor muscle training, fluid management) should be offered as first-line therapy to all patients with overactive bladder. Antimuscarinic agents may be used in combination with behavioral strategies. Limited evidence suggests that initiating behavioral and pharmacologic therapy simultaneously may improve outcomes, including frequency, voided volume, incontinence, and symptom distress.[127]

PHARMACOTHERAPY

Anticholinergic therapy

Anticholinergic medications block the acetylcholine neurotransmitter synapse within the central and peripheral nervous systems, inhibiting parasympathetic activity, thereby reducing the involuntary movement of smooth muscles like those present within the bladder.[117,118] Multiple anticholinergic medications are available to be used in clinical practice. As a result,

the bladder's ability to contract is decreased. Such medications include non-selective agents (oxybutynin, tolterodine) or moreselective agents (solifenacin, darifenacin)[117,118] Antimuscarinics are also often competitive antagonists. This means that when there is a large amount of ACh released, such as during micturition, the medications effects should be reduced; otherwise, the detrusor's reduced ability to contract might eventually lead to urine retention.[128]

Muscarinic receptors are located on the urothelial cells of the bladder, where their density is even higher than in the detrusor muscle.[129,130] Antimuscarinics are classified as either tertiary or quaternary amines.[131,132] Lipophilicity, molecule charge, and even molecular size varies between them, with tertiary compounds having higher lipophilicity and molecular charge than quaternary agents. Tertiary amines include atropine, darifenacin, fesoterodine (and its active metabolite 5hydroxymethyl-tolterodine), oxybutynin, propiverine, solifenacin, and tolterodine. They are typically easily absorbed from the gastrointestinal tract and, depending on their specific physicochemical qualities, should potentially be able to enter into the central nervous system (CNS). High lipophilicity, small molecular size, and low charge will enhance the chances of passing across the blood–brain barrier, although active transport out of the CNS by the MDR1 gene product will counterbalance this for some medications.[133]

Propantheline and trospium are quaternary ammonium compounds that are poorly absorbed, only pass through the CNS to a limited extent, and have a low incidence of CNS adverse effects.[131] They still cause well-known antimuscarinic side effects include accommodation paralysis, constipation, tachycardia, and mouth dryness. The P450 enzyme system converts several antimuscarinics into active and/or inactive metabolites. CYP2D6 and CYP3A4 are the most typically implicated P450 enzymes. The metabolic conversion raises the possibility of drug–drug interactions, with the antimuscarinic and/or interacting drug's plasma concentration/effect being lowered (enzyme induction) or raised (enzyme inhibition, substrate competition).[131] Antimuscarinics released by the renal tubules (e.g., trospium) might hypothetically obstruct the clearance of other medicines by this mechanism.

Darifenacin: Darifenacin has a high selectivity for M3 receptors, which are the most significant receptors for detrusor contraction, which could enhance efficacy and minimize side effects associated with antagonistic interactions with other receptor subtypes.[151] Darifenacin is actively removed from the brain via a protein-mediated transporter mechanism, similar to that used to remove trospium and fesoterodine.[150]

Fesoterodine is a muscarinic receptor antagonist which is non-subtype selective.[152] It's a prodrug this is rapidly degraded by ubiquitous esterases into 5-hydroxymethyl tolterodine (5-HMT), the same active metabolite of tolterodine.[153]

Oxybutynin is the earliest OAB medication, and it is still the first or second most commonly given medication in many countries.[154-157] It's an antimuscarinic drug with strong independent musculotropic relaxant and local anaesthetic properties.[158,159] The CYP system converts it to N-desethyloxybutynin (DEO), which is its major metabolite.[160] Oral formulations in the IR and ER, as well as a transdermal administration method and a transdermal gel formulation.[161-163] In compared to oral treatment, transdermal administration modifies the drug's metabolism, resulting in a lower rate of dry mouth. Pruritus and erythema at the application site are the most typical side effects.[164]

Transdermal formulations: Transdermal preparations of oxybutynin offer the benefit of bypassing hepatic breakdown by CYP3A4 enzymes, hence enhancing oxybutynin bioavailability and reducing the blood levels of DEO, the metabolite that is primarily responsible for the drug's negative effects.[172,173] It may improve the patient's tolerance while preserving effectiveness.[173-175] The risk of dry mouth is lowered to around 7%, which is much less than that seen with oral formulations.[176] Propiverine is a nonselective antimuscarinic drug that acts as a musculotropic smooth muscle relaxant.[165] It also contains calcium antagonistic and alpha(1)-adrenoceptor antagonistic activities, although their importance in terms of clinical consequences is unclear.[166]

Trospium is a hydrophilic quaternary amine that has difficulty penetrating though blood-brain barrier.[150,167] As a result, there is a low risk of inducing cognitive impairment.[168,169] Trospium lacks muscarinic subtype selectivity and is metabolised seldom by the hepatic cytochrome P450 system, resulting in a decreased risk of drug-drug interactions, which may be beneficial in the setting of polypharmacy.[170] Renal tubular secretion primarily eliminates it intact in the urine, however it is uncertain if this contributes to its therapeutic efficacy.[171]

Non-selective agents are effective, with a hit rate of >65%.[119]

Medication class	Agent	Route, dose	Adverse effects
Anticholinergic, non-selective	Oxybutynin	Oral, 5 mg three times daily	Dry mouth, constipation, blurred vision, drowsiness, delirium
		Topical, 3.9 mg/ 24 hours	Skin reaction, dry mouth, constipation, blurred vision, drowsiness, delirium
		Oxybutynin patch 1 patch changed twice weekly (3.9 mg/day) Rotate application site	Dry mouth Constipation Cognitive: no effect Application site pruritis/erythema
Anticholinergic, M3 selective	Solifenacin	Oral, 5–10 mg daily	Severe hepatic impairment
	Darifenacin	7.5–15 mg daily	Dry mouth Constipation Cognitive: no effect
Beta-3 agonist	Mirabegron	Oral, 25–50 mg daily	Hypertension, long QT syndrome
	Botulinum toxin A (Botox®)	100–200 U idiopathic OAB 200–300 U neurogenic OAB	• Urinary retention (elevated PVR ± need for CIC) • Hematuria • Urinary tract infection
	Desmopressin	0.1–0.2 mg daily Concurrently reduce fluid intake to avoid hyponatremia/ water intoxication	Hyponatremia •Cardiac failure •Hypertension

Non-selective agents are effective, with a hit rate of >65%.[119]

Beta-3 agonist therapy Beta-3 adrenergic receptor agonists upregulate sympathetic activity, thereby promoting detrusor smooth muscle relaxation and consequently reducing muscle spasms.[119] The current commercially available β3 adrenoceptor agonist is mirabegron. It works via a special path to anticholinergic agents by relaxing the detrusor muscle, allowing higher bladder volumes before the necessity for urination.[117-119] The stimulation of adenylyl cyclase, which results in the production of cAMP, leads to detrusor relaxation, according to the widely established mechanism of action of 3-AR agonists.[177] A recent research found 3-AR expression in cholinergic nerve terminals of the human bladder, suggesting that this receptor may play a role in acetylcholine release control.[178]

The function of 3-AR expressed in sensory fibres and urothelial cells is unclear. 3AR are predominantly expressed outside of the bladder in adipose tissue, the gastrointestinal tract and gallbladder, the uterus, and the central nervous system.[177]

Minimally invasive options:- Intravesical botulinum toxin A

Botulinum toxin A bladder injections administered via cystoscopy into the wall of the bladder inhibit muscle contractions and suppress bladder activity.[121] The treatment is usually effective for 6–12 months,but the procedure are often repeated. half the patients treated with intravesical neurotoxin A reported improvement in symptoms of OAB.[120,121]

Sacral nerve stimulation

For spinal nerve stimulation, surgeons implant an electrode within the S3–S4 sacral foramen with the aim of manipulating the sensory pathway of the bladder innervation.[122] After the battery has reached the end of its life cycle, the gadget will need to be replaced, which takes on average 62.5 months.[146] Medtronic, the producer of the InterStim device, advises against using MRI in patients who have the device.[147] They only allow MRI of the head if the gadget is switched off and a magnet of 1.5 Tesla or less is employed.

Axonics just released an implanted rechargeable SNM device on the market. This has replaced the InterStim's limited battery life with a rechargeable lithium ion battery that can last up to 15 years or more.[148] The battery should last 2 weeks with normal use before needing to be recharged. This takes 1 to 2 hours and is done with a wireless charger.[149] The implantation method was planned to be almost comparable to that of the InterStim.[149]

Peripheral tibial nerve stimulation:-For peripheral tibial nerve stimulation (PTNS), an electrode is inserted into the skin 5 cm above the medial malleolus. By way of an electrode, a retrograde stimulation is generated through the tibial nerve to the plexus sacralis. The nerve is increasingly stimulated until big toe flexion, toe abduction or leg extension, at which era the amplitude is reduced by one level and therefore the treatment continues for half-hour.[123] Under local anaesthetic, the implant is surgically implanted. 3 cm superior and 2 cm posterior to the medial malleolus, an incision is made. The electrode is attached using a non-absorbable suture near the tibial nerve. To activate the electrodes, an external control unit is worn around the ankle. This device is worn for 30 minutes six times a week to trigger therapy.[142,143] At three months, a study of 15 patients (13 females) found a substantial reduction in the frequency, urgency, and urgent incontinence events.[143] The quality of life has also improved significantly. Three patients required antibiotics for a week and three patients required analgesics for a week. Although cultures were negative, one gadget was removed because it was suspected of being infected. The gadget was not difficult to operate for any of the patients.

The implant was tested in 36 individuals over the course of six months.[144] At 6 months, 71 percent of patients had achieved clinical success (>50 percent decrease). The number of leaks per day, the severity of the leaks, the frequency of leaks, the degree of urgency, and the number of pad changes per day all decreased dramatically. Patients with urgency incontinence were found to be dry in 28% of cases. The results of the OAB-q questionnaire improved significantly. In 47 percent of patients, there were adverse events: 14 percent experienced discomfort, 22 percent had a suspected infection, and 8% had wound issues. The implant was removed in one patient due to discomfort and edoema, although cultures revealed no infection. In a three-year follow-up study, 20 participants from the prior trial were included.[145] A total of 75% of people had a >50% reduction in their symptoms, as well as a substantial increase in their quality of life. The majority of patients were satisfied in some way. Between 6 months and 3 years, no adverse events were observed.

Invasive surgical options:-When conservative and minimally invasive treatments have failed, bladder augmentation cystoplasty could also be considered to treat enuresis caused by bladder disorder dysfunction, significantly contracted bladder caused by inflammatory conditions, interstitial cystitis and reconstruction after bladder injury.[124] This procedure involves bladder enlargement by adding a bit of bowel into the bladder wall.

Patients with recalcitrant incontinence who are not fit for enlargement or other preoccupations may advantage from a long-term large-bore (18–24 FG) suprapubic catheter. The suprapubic catheter is related with comparable disease rates and coming about complications as long-term urethral catheterization.[125] Patients will moreover ought to be able to care, or have carers able to care, for a leg sack and night bag[125] In extraordinary cases of severe OAB headstrong to all other treatment, urinary redirection within the frame of an ileal conduit with or without cystectomy may be considered after careful guiding in a high-volume centre.[124-126]

RECENT ADVANCEMENTS

1) SELECTIVE BLADDER DENERVATION: bladder denervation on a case-by-case basis

Radiofrequency ablation of the bladder's sub-trigone region, which contains afferent sensory nerves 54, is used in selective bladder denervation (SBD). Under cystoscopic supervision, the gadget is placed to the trigone. 5 mm below the ureteric orifice, the heat delivery probe is placed along the left edge of the trigone.[134] Ablation commences after the electrodes are advanced three millimetres into the urothelium. This is replicated on the trigone's right edge and at numerous locations in between.

This treatment was given to a total of 63 patients with refractory OAB. Frequency, urgency events, and urgency incontinence episodes all decreased significantly after 12 weeks. With no significant difference in post void residuals, ablation for 60 seconds improved urgency incontinence episodes and quality of life scores much more than ablation for 10 seconds. Over the course of 5 days, there was very little pain following the treatment.

2) TREATMENT WITH LASER

Einstein defined light amplification by stimulated emission of radiation (laser) for the first time in 1917. It's utilised for a variety of medical purposes. Microablative fractional CO 2 laser (SmartXide 2-V 2LR, MonaLisa Touch; DEKA, Florence, Italy) and non-ablative photothermal erbium:YAG (Er:YAG) laser (Fotona Smooth XS; Fotona, Ljubljana, Slovenia) are the two most often used lasers . The laser generates thermomodulation by heating and ablating tissue columns (in the case of the CO 2 laser).[135]

Thirty postmenopausal women with vulvovaginal atrophy and OAB were enrolled in a prospective observational pilot research.[136] They received three CO_2 laser treatments spaced

30 days apart. The surgery was carried out without analgesics or anaesthesia in an ambulatory Drug. Bladder diary values, number of urgency episodes, urgent incontinence events all improved significantly.

RECENT ADVANCEMENTS IN THE PHARMACOTHERAPY

As we have seen the pharmacotherapy mentioned above, there are two major classes of drugs used, which are the Anticholinergics and the Beta 3 agonists.

1) There has been an advancement in the Beta 3 agonists but not the Anticholinergics. Since 2013, mirabegron, a beta-3 agonist, has been utilised as an anticholinergic alternative.[137] In September 2018, Japan approved vibegron, a selective beta-3 adrenoreceptor agonist, for the treatment of OAB.[138] It is unlikely to be metabolised by CYP3A4 or CYP2D6[139], *thus medication interactions are unlikely. Mirabegron suppresses CYP2D6 and can cause drug interactions which is not the case in vibegron.*[140] The most common interactions are which occur with metoprolol and Tolterodine. It is common in patients suffering from neuronal disorders like schizophrenia, depression, anxiety to have urinary incontinence for which mirabegron is commomly used and may cause several interactions like increased exposure of the drug used for that particular disorder.

In the bladder, transient receptor potential (TRP) channels are numerous. They've been linked to mechanotransduction, pain, and temperature sensing, therefore their activity is fairly varied.[189] Because normal bladder feeling is believed to be compromised in OAB, modifying afferent brain transmission via TRP receptor modulation might theoretically improve OAB symptomatology. TRPV1, which is desensitised by agonists like capsaicin and resiniferotoxin, is perhaps the most wellknown of the TRP receptors. Both have showed potential in treating symptoms of neurogenic detrusor overactivity, but the availability of intradetrusor botulinum toxin has rendered them rather outdated. Because of the discomfort associated with TRPV1 agonist treatment, they are not suited for idiopathic OAB. TRPV1 inhibitors, on the other hand, may prove to be a far better alternative. In both preclinical and clinical investigations, a number of TRPV1 inhibitors have been studied.[190] Although the effect of TRPV1 inhibition on bladder function in humans has not been studied, multiple animal studies have shown that oral, intravesical, and intravenous TRPV1 treatment decreases detrusor contractility and increases bladder capacity. The development of hyperthermia is one obstacle to TRPV1 inhibitor usage in people, however newer inhibitors tested in human subjects do not appear to have this side effect.[191] While TRPV1 is likely the

most well-studied member of the TRP family in terms of lower urinary tract function, the bladder has numerous additional TRP receptors, including TRPV4, TRPM8, TRPA1, and TRPM4. All of these have been tested in vitro or in animal models with varying degrees of effectiveness, and research into their potential role in OAB is still underway.[190]

2) Inhibitors of Phosphodiesterase Type 5:- Erectile dysfunction is treated with phosphodiesterase type 5 inhibitors (PDE5Is).The effectiveness and safety of daily low-dose tadalafil for 96 female patients with OAB were evaluated in a randomised, double-blind, placebo-controlled experiment.[1] The overactive bladder symptom score and the Indevus Urgency Severity Scale both improved significantly. When compared to baseline and placebo, there were substantial reductions in OAB symptoms. There were no major side effects noted. The detrusor muscle contraction is hypothesised to be reduced by tadalafil. These drugs are not currently recommended as first-line treatment for OAB.
3) Potassium channels are distributed throughout the bladder and play a significant role in the depolarization and repolarization of the detrusor muscle. In able-bodied OAB participants, a recent Phase I investigation with an injectable potassium channel gene plasmid vector shown satisfactory safety and a moderate reduction in urgency and voiding episodes. Despite these encouraging results with an injectable formulation, highly selective oral potassium channel antagonists are unlikely to be created in the near future. There are a slew of other molecular targets for OAB treatment.[179] Purinergic receptor blockers, TGF-beta pathway modulators, and Rho-kinase inhibitors are only a few examples. These targets are still in the early stages of development, and only preclinical or in vitro research has been done to see if they can help with bladder dysfunction.[180]
4) P2X3 receptors bind urothelial ATP and are involved in the activation of suburothelial sensory fibres, which provide bladder feeling and trigger the micturition reflex. As a result, P2X3 antagonists may offer a new therapy option for OAB. Preclinical studies using P2X3 receptor agonists and P2X3 deletion mice revealed a decrease in voiding frequency and an increase in bladder volume thresholds without affecting the amplitude of detrusor contractions.[181] Urinary urgency was significantly reduced in preliminary human tests, according to clinical data.[182] In Europe, more clinical studies are being conducted.
5) Another potential target for OAB treatment is the cannabinoid receptor. These receptors are found in the human bladder and urethra, and they have been found to be elevated in the detrusor and sub-urothelial layers of painful bladder syndrome and OAB patients as

compared to healthy controls.[183] Although the function of cannabinoid receptors in the urothelium is unknown, it is assumed that activation of these receptors reduces afferent neuronal transmission by reducing the production of activating neuropeptides such as CGRP and adenosine triphosphate (ATP).[184-186] In an animal model investigation, activation of cannabinoid receptors was observed to enhance bladder capacity and reduce maximum voiding pressures.[187] Patients with multiple sclerosis have been the primary participants of human translation studies. In a 2016 research of 15 individuals, cannabidiol/ tetrahydrocannabinol (THC/ CBD) oral-mucosal spray was observed to reduce overactive bladder symptoms after four weeks of use. There was a little increase in maximal bladder capacity and bladder volume at initial desire to pee, although it was not statistically significant.[188] The use of cannabinoid receptor agonists in able-bodied OAB people raises obvious safety issues, but the discovery of selective activators with no systemic effects is a sustainable future route.

REFERENCES

1. Abrams P, Cardozo L, Fall M, et al: The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-Committee of the International Continence Society. Neurourol Urodyn, 2002; 21: 167–178.
2. Homma, Yukio et al. "Symptom Assessment Tool For Overactive Bladder Syndrome—Overactive Bladder Symptom Score". *Urology*, 2006; 68(2): 318-323. *Elsevier BV*, doi:10.1016/j.urology.2006.02.042. Accessed 30 Nov 2021.
3. Abrams P, Wein AJ, eds. The Overactive Bladder: From Basic Science to Clinical Management Consensus Conference. Urology, 1997; 50: 1-114.
4. Idem. Overactive Bladder and Its Treatments Consensus Conference. Urology, 2000; 55: 1-84.
5. Staskin DR, Wein AJ, eds. New perspectives on the overactive bladder. Urology, 2002; 60: 1-104.
6. Wein, A. and Rovner, E. "Definition and epidemiology of overactive bladder", *Urology*, 2002; 60(5): 7-12. doi: 10.1016/s0090-4295(02)01784-3.
7. Marinkovic, S. et al. "The management of overactive bladder syndrome", *BMJ*, 2012; 344(apr17 1): e2365-e2365. doi: 10.1136/bmj.e2365.
8. Leron, E. et al. "Overactive Bladder Syndrome: Evaluation and Management", *Current Urology*, 2018; 11(3): 117-125. doi: 10.1159/000447205.

9. Onukwugha E, Zuckerman IH, McNally D, Coyne KS, Vats V, Mullins CD. The total economic burden of overactive bladder in the United States: a diseasespecific approach. *Am J Manag Care.*, 2009; 15(4): S90–97.
10. Marinkovic SP, Rovner ES, Moldwin RM, Stanton SL, Gillen LM, Marinkovic CM. The management of overactive bladder syndrome. *BMJ.*, 2012; 344: e2365.
11. Gormley EA, Lightner DJ, Faraday M, Vasavada SP. "Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment". *The Journal of Urology*, May, 2015; 193(5): 1572–80.
12. *Danforth's Obstetrics and Gynecology* (2021). Available at: https:// books.google.co.in/books? id=v4krPhqFG8sC&pg=PA890&redir_esc=y#v=onepage&q&f=false (Accessed: 1 December 2021).
13. *Wayback Machine* (2021). Available at: https://web.archive.org/web/20150426225530/http://www.auanet.org/common/pdf/education/clinicalguidance/ Overactive-Bladder.pdf (Accessed: 1 December 2021).
14. Kobelt G. Economic considerations and outcome measurement in urge incontinence. Urology, 1997; 50: 100-10.
15. Brown JS, Posner SF, Stewart AL. Urge incontinence: new health-related quality of life measures. J Am Geriatr Soc., 1999; 47: 980-8.
16. DuBeau CE, Kiely DK, Resnick NM. Quality of life impact of urge incontinence in older persons: a new measure and conceptual structure. J Am Geriatr Soc., 1999; 47: 989-94.
17. Dugan E, Cohen SJ, Bland DR, et al. The association of depressive symptoms and urinary incontinence among older adults. J Am Geriatr Soc., 2000; 48: 413-6.
18. Coyne KS, Sexton CC, Bell JA, Thompson CL, Dmochowski R, Bavendam T, et al. The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial/ethnic group and age: results from OAB-POLL. *Neurourol Urodyn*, 2013; 32(3): 230–237. [PubMed] [Google Scholar] The OAB-POLL study is one of the most recent population-based studies to specifically examine the impact of OAB on work productivity and physical activity.
19. Dooley Y, Kenton K, Cao G, Luke A, Durazo-Arvizu R, Kramer H, et al. Urinary incontinence prevalence: results from the National Health and Nutrition Examination Survey. *J Urol.*, 2008; 179(2): 656–661.

20. Coyne KS, Margolis MK, Kopp ZS, Kaplan SA. Racial differences in the prevalence of overactive bladder in the United States from the epidemiology of LUTS (EpiLUTS) study. *Urology*, 2012; 79(1): 95–101.
21. Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder and other lower urinary tract symptoms in five countries: results of the EPIC study. *Eur Urol.*, 2006; 50(6): 1306–1315.
22. Lapitan, M. and Chyeon, P. "The Epidemiology of Overactive Bladder among Females in Asia: A Questionnaire Survey", *International Urogynecology Journal and Pelvic Floor Dysfunction*, 2001; 12(4): 226-231. doi: 10.1007/ s001920170043.
23. Hampel C, Gillitzer R, Pahernik S, Hohenfellner M, Thüroff JW. Epidemiologie und Atiologie der instabilen Blase [Epidemiology and etiology of overactive bladder]. Urologe A., Jun, 2003; 42(6): 776-86. German. doi: 10.1007/ s00120-0030360-1. Epub 2003 Apr 29. PMID: 12851768.
24. Brading AF. A myogenic basis for the overactive bladder. Urology, 1997; 50: 57–67; discussion 68–73.
25. German K, Bedwani J, Davies J, Brading AF, Stephenson TP. Physiological and morphometric studies into the pathophysiology of detrusor hyperreflexia in neuropathic patients. *J Urol.*, 1995; 153: 1678–83.
26. Mills IW, Greenland JE, McMurray G *et al.* Studies of the pathophysiology of idiopathic detrusor instability: the physiological properties of the detrusor smooth muscle and its pattern of innervation. *J Urol.*, 2000; 163: 646– 51.
27. Sui G, Fry CH, Malone-Lee J, Wu C. Aberrant Ca2+ oscillations in smooth muscle cells from overactive human bladders. *Cell Calcium*, 2009; 45: 456– 64.
28. https://my.clevelandclinic.org/health/diseases/14248--overactive-bladder-#:~:text=Overactive%20bladder%20describes%20a%20combination,Lifestyle%20changes%20may%20help.
29. https://www.healthline.com/health/overactive-bladder
30. https://www.medicalnewstoday.com/articles/316782
31. https://www.powerofpositivity.com/causes-overactive-bladder/
32. Overactive bladder Disease Reference Guide - Drugs.com
33. Overactive bladder Disease Guide - Drugs.com
34. Overactive Bladder: Medications, Symptoms & Treatment (emedicinehealth.com)
35. Brading AF. A myogenic basis for the overactive bladder. *Urology*, 1997; 50: 57–67; discussion 68–73.

36. Brading A. Overactive bladder: why it occurs. *Women's Health Med.*, 2005; 2: 20–3.
37. Brading AF, Symes S. Ischemia as an etiological factor in bladder instability: implications for therapy. *Adv Exp Med Biol.*, 2003; 539: 255–69.
38. German K, Bedwani J, Davies J, Brading AF, Stephenson TP. Physiological and morphometric studies into the pathophysiology of detrusor hyperreflexia in neuropathic patients. *J Urol.*, 1995; 153: 1678–83.
39. Mills IW, Greenland JE, McMurray G *et al.* Studies of the pathophysiology of idiopathic detrusor instability: the physiological properties of the detrusor smooth muscle and its pattern of innervation. *J Urol*, 2000; 163: 646– 51.
40. Sibley GN. Developments in our understanding of detrusor instability. *Br J Urol*, 1997; 80(1): 54– 61.
41. Sui G, Fry CH, Malone-Lee J, Wu C. Aberrant Ca2+ oscillations in smooth muscle cells from overactive human bladders. *Cell Calcium*, 2009; 45: 456–64.
42. de Groat WC. A neurologic basis for the overactive bladder. *Urology*, 1997; 50: 36–52; discussion, 53–56.
43. Kessler TM, Burkhard FC, Z'Brun S *et al.* Effect of thalamic deep brain stimulation on lower urinary tract function. *Eur Urol*, 2008; 53: 607–12.
44. Griffiths D, Tadic SD. Bladder control, urgency, and urge incontinence: evidence from functional brain imaging. *Neurourol Urodyn*, 2008; 27: 466–74.
45. O'Reilly BA, Kosaka AH, Knight GF *et al.* P2X receptors and their role in female idiopathic detrusor instability. *J Urol.*, 2002; 167: 157–64.
46. Yoshimura N. Lower urinary tract symptoms (LUTS) and bladder afferent activity. *Neurourol Urodyn*, 2007; 26: 908–13.
47. De Laet K, De Wachter S, Wyndaele JJ. Systemic oxybutynin decreases afferent activity of the pelvic nerve of the rat: new insights into the working mechanism of antimuscarinics. *Neurourol Urodyn*, 2006; 25: 156–61.
48. Aizawa N, Igawa Y, Nishizawa O, Wyndaele JJ. Effects of CL316,243, a beta 3adrenoceptor agonist, and intravesical prostaglandin E2 on the primary bladder afferent activity of the rat. *Neurourol Urodyn*, 2010; 29: 771–6.
49. Hougaard C, Fraser MO, Chien C *et al.* A positive modulator of K Ca 2 and K Ca 3 channels, 4,5-dichloro-1,3-diethyl-1,3-dihydro-benzoimidazol-2-one (NS4591), inhibits bladder afferent firing in vitro and bladder overactivity in vivo. *J Pharmacol Exp Ther.*, 2009; 328: 28–39.

50. Maggi CA, Santicioli P, Parlani M, Astolfi M, Patacchini R, Meli A. The presence of mucosa reduces the contractile response of the guinea-pig urinary bladder to substance P. *J Pharm Pharmacol*, 1987; 39: 653–5.
51. Birder LA, de Groat WC. Mechanisms of disease: involvement of the urothelium in bladder dysfunction. *Nat Clin Pract Urol*, 2007; 4: 46–54.
52. Meng E, Young JS, Brading AF. Spontaneous activity of mouse detrusor smooth muscle and the effects of the urothelium. *Neurourol Urodyn*, 2008; 27: 79–87.
53. Shioyama R, Aoki Y, Ito H *et al.* Long-lasting breaches in the bladder epithelium lead to storage dysfunction with increase in bladder PGE2 levels in the rat. *Am J. Physiol Regul Integr Comp Physiol* 2008; 295: R714– 8.
54. Wang EC, Lee JM, Johnson JP, Kleyman TR, Bridges R, Apodaca G. Hydrostatic pressure-regulated ion transport in bladder uroepithelium. *Am J Physiol Renal Physiol*, 2003; 285: F651–63.
55. Birder LA, Kanai AJ, de Groat WC *et al.* Vanilloid receptor expression suggests a sensory role for urinary bladder epithelial cells. *Proc Natl Acad Sci USA*, 2001; 98: 13396–401.
56. Everaerts W, Gevaert T, Nilius B, De Ridder D. On the origin of bladder sensing: Tr(i)ps in urology. *Neurourol Urodyn*, 2008; 27: 264–73.
57. Lips KS, Wunsch J, Zarghooni S *et al.* Acetylcholine and molecular components of its synthesis and release machinery in the urothelium. *Eur Urol.*, 2007; 51: 1042–53.
58. Chuang YC, Thomas CA, Tyagi S, Yoshimura N, Tyagi P, Chancellor MB. Human urine with solifenacin intake but not tolterodine or darifenacin intake blocks detrusor overactivity. *Int Urogynecol J Pelvic Floor Dysfunct*, 2008; 19: 1353–7.
59. Abrams PH, Farrar DJ, Turner-Warwick RT *et al.* The results of prostatectomy: a symptomatic and urodynamic analysis of 152 patients. *J Urol*, 1979; 121: 640–2.
60. de Nunzio C, Franco G, Rocchegiani A *et al.* The evolution of detrusor overactivity after watchful waiting, medical therapy and surgery in patients with bladder outlet obstruction. *J Urol*, 2003; 169: 535–9.
61. Seki N, Kai N, Seguchi H *et al.* Predictives regarding outcome after transurethral resection for prostatic adenoma associated with detrusor underactivity. *Urology*, 2006; 67: 306–10.
62. Van Venrooij GE, Van Melick HH, Eckhardt MD *et al.* Correlations of urodynamic changes with changes in symptoms and well-being after transurethral resection of the prostate. *J Urol.*, 2002; 168: 605–9.

63. Seaman EK, Jacobs BZ, Blaivas JG *et al.* Persistence or recurrence of symptoms after transurethral resection of the prostate: a urodynamic assessment. *J Urol,* 1994; 152: 935–7.
64. Steers WD, De Groat WC. Effect of bladder outlet obstruction on micturition reflex pathways in the rat. *J Urol,* 1988; 140: 864–71.
65. Steers WD, Kolbeck S, Creedon D *et al.* Nerve growth factor in the urinary bladder of the adult regulates neuronal form and function. *J Clin Invest,* 1991; 88: 1709–15.
66. Caterina MJ, Schumacher MA, Tominaga M *et al.* The capsaicin receptor: a heatactivated ion channel in the pain pathway. *Nature,* 1997; 389: 816–24.
67. Kim JC, Kim DB, Seo SI *et al.* Nerve growth factor and vanilloid receptor expression, and detrusor instability, after relieving bladder outlet obstruction in rats. *BJU Int.,* 2004; 94: 915– 8.
68. Baker SA, Hatton WJ, Han J *et al.* Role of TREK-1 potassium channel in bladder overactivity after partial bladder outlet obstruction in mouse. *J Urol,* 2010; 183: 793–800.
69. Baker SA, Hennig GW, Han J *et al.* Methionine and its derivatives increase bladder excitability by inhibiting stretch-dependent K(+) channels. *Br J Pharmacol,* 2008; 153: 1259– 71.
70. Kita M, Yunoki T, Takimoto K *et al.* Effects of bladder outlet obstruction on properties of Ca2+-activated K+ channels in rat bladder. *Am J Physiol Regul Integr Comp Physiol,* 2010; 298: R1310–9.
71. Chess-Williams R. Muscarinic receptors of the urinary bladder: detrusor, urothelial and prejunctional. *Auton Autacoid Pharmacol,* 2002; 22: 133–45.
72. Andersson KE, Yoshida M. Antimuscarinics and the overactive detrusor—which is the main mechanism of action? *Eur Urol,* 2003; 43: 1–5.
73. de Groat WC. The urothelium in overactive bladder: passive bystander or active participant? *Urology,* 2004; 64(1): 7–11.
74. Jiang LH, Kim M, Spelta V *et al.* Subunit arrangement in P2X receptors. *J Neurosci,* 2003; 23: 8903–10.
75. North RA, Surprenant A. Pharmacology of cloned P2X receptors. *Annu Rev Pharmacol Toxicol,* 2000; 40: 563–80.
76. Cook SP, McCleskey EW. ATP, pain and a full bladder. *Nature,* 2000; 407: 951–2.
77. Zhong Y, Banning AS, Cockayne DA *et al.* Bladder and cutaneous sensory neurons of the rat express different functional P2X receptors. *Neuroscience,* 2003; 120: 667–75.

78. Kim JC, Yoo JS, Park EY *et al.* Muscarinic and purinergic receptor expression in the urothelium of rats with detrusor overactivity induced by bladder outlet obstruction. *BJU Int.*, 2008; 101: 371–5.
79. Liu G, Daneshgari F. Alterations in neurogenically mediated contractile responses of urinary bladder in rats with diabetes. *Am J Physiol Renal Physiol*, 2005; 288: F1220–6.
80. Wang CC, Nagatomi J, Toosi KK *et al.* Diabetes-induced alternations in biomechanical properties of urinary bladder wall in rats. *Urology*, 2009; 73: 911–5.
81. Tong YC, Cheng JT, Hsu CT. Alterations of M(2)-muscarinic receptor protein and mRNA expression in the urothelium and muscle layer of the streptozotocininduced diabetic rat urinary bladder. *Neurosci Lett.*, 2006; 406: 216–21.
82. Cheng JT, Yu BC, Tong YC. Changes of M3-muscarinic receptor protein and mRNA expressions in the bladder urothelium and muscle layer of streptozotocininduced diabetic rats. *Neurosci Lett.*, 2007; 423: 1–5.
83. Tong YC, Cheng JT. Alterations of M2,3-muscarinic receptor protein and mRNA expression in the bladder of the fructose fed obese rat. *J Urol*, 2007; 178: 1537–42.
84. Lee WC, Chien CT, Yu HJ, Lee SW. Bladder dysfunction in rats with metabolic syndrome induced by long-term fructose feeding. *J Urol.*, 2008; 179: 2470–6.
85. Lee WC, Chuang YC, Chiang PH, Chien CT, Yu HJ, Wu CC. Pathophysiological studies of overactive bladder and bladder motor dysfunction in a rat model of metabolic syndrome. *J Urol*, 2011; 186: 318–25.
86. Nobe K, Yamazaki T, Kumai T *et al.* Alterations of glucose-dependent and independent bladder smooth muscle contraction in spontaneously hypertensive and hyperlipidemic rat. *J Pharmacol Exp Ther.*, 2008; 324: 631–42.
87. Yoshida M, Masunaga K, Nagata T, Satoji Y, Shiomi M. The effects of chronic hyperlipidemia on bladder function in myocardial infarction-prone Watanabe heritable hyperlipidemic (WHHLMI) rabbits. *Neurourol Urodyn*, 2010; 29: 1350–4.
88. Azadzoi KM, Shinde VM, Tarcan T *et al.* Increased leukotriene and prostaglandin release, and overactivity in the chronically ischemic bladder. *J Urol*, 2003; 169: 1885–91.
89. Azadzoi KM, Radisavljevic ZM, Golabek T *et al.* Oxidative modification of mitochondrial integrity and nerve fiber density in the ischemic overactive bladder. *J Urol*, 2010; 183: 362– 9.
90. Kershen RT, Azadzoi KM, Siroky MB. Blood flow, pressure and compliance in the male human bladder. *J Urol*, 2002; 168: 121–5.

91. Kupelian V, McVary KT, Barry MJ *et al.* Association of C-reactive protein and lower urinary tract symptoms in men and women: results from Boston area community health survey. *Urology*, 2009; 73: 950–7.
92. Chuang YC, Tyagi V, Liu RT, Chancellor MB, Tyagi P. Urine and serum Creactive protein levels as potential biomarkers of lower urinary tract symptoms. *Urol Sci.,* 2010; 21: 132– 6.
93. McMahon SB, Dmitrieva N, Koltzenburg M. Visceral pain. *Br J Anaesth.,* 1995; 75.
94. Dmitrieva N, Shelton D, Rice ASC, McMahon SB. The role of nerve growth factor in a model of visceral inflammation. *Neuroscience.,* 1997; 78: 449–59.
95. Chuang YC, Fraser MO, Yu Y, Chancellor MB, de Groat WC, Yoshimura N. The role of bladder afferent pathways in the bladder hyperactivity induced by intravesical administration of nerve growth factor. *J Urol,* 2001; 165: 975–9.
96. Seki S, Sasaki K, Fraser MO *et al.* Immunoneutralization of nerve growth factor in lumbosacral spinal cord reduces bladder hyperreflexia in spinal cord injured rats. *J Urol.,* 2002; 168: 2269–74.
97. Clemow DB, Steers WD, McCarty R, Tuttle JB. Altered regulation of bladder nerve growth factor and neurally mediated hyperactive voiding. *Am J Physiol,* 1998; 275: R1279–86.
98. Andersson KE, Wein AJ. Pharmacology of lower urinary tract: basis for current and future treatments of urinary incontinence. *Pharmacol Rev.,* 2004; 56: 581–631.
99. Lee T, Andersson KE, Streng T, Hedlund P. Simultaneous registration of intraabdominal and intravesical pressures during cystometry in conscious rats— effects of bladder outlet obstruction and intravesical PGE2. *Neurourol Urodyn*, 2008; 27: 88–95.
100. Schussler B. Comparison of the mode of action of prostaglandin E2 (PGE2) and sulprostone, a PGE2-derivative, on the lower urinary tract in healthy women. A urodynamic study. *Urol Res.,* 1990; 18: 349–52.
101. Kim JC, Park EY, Seo SI, Park YH, Hwang TK. Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder. *J Urol,* 2006; 175: 1773– 6.
102. Liu HT, Kuo HC. Urinary nerve growth factor level could be a potential biomarker for diagnosis of overactive bladder. *J Urol,* 2008; 179: 2270–4.
103. Liu HT, Chancellor MB, Kuo HC. Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection. *Eur Urol,* 2009; 56: 700–6.

104. Liu HT, Chancellor MB, Kuo HC. Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder. *BJU Int.*, 2009; 103: 1668–72.
105. Tyagi P, Barclay D, Zamora R *et al.* Urine cytokines suggest an inflammatory response in the overactive bladder: a pilot study. *Int Urol Nephrol*, 2010; 42: 629–35.
106. Apostolidis A, Jacques TS, Freeman A *et al.* Histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity. *Eur Urol*, 2008; 53: 1245–53.
107. Thüroff JW, Abrams P, Andersson KE, Artibani W, Chapple CR, Drake MJ, et al. The European guidelines on urinary incontinence. Actas Urologicas Espanolas, 2011; 35: 373-88.
108. Yamaguchi O, Nishizawa O, Takeda M, Yokoyama O, Homma Y, Kakizaki H, et al. Clinical guidelines for overactive bladder. The Japanese Urological Society. Int J Urol., 2009; 16: 126-42.
109. Ouslander JG. Management of overactive bladder. N Engl J Med., 2004; 350: 786-99.
110. Hashim H, Abrams P. How should patients with an overactive bladder manipulate their fluid intake. BJU Int, 2008; 102: 62-6.
111. Lohsiriwat S, Hirunsai M, Chaiyaprasithi B. Effect of caffeine on bladder function in patients with overactive bladder symptoms. Urol Ann, 2011; 3: 14-8.
112. Vella VL, Jaffe W, Lidicker J, Meilahn J, Dandolu V. Prevalence of urinary symptoms in morbidly obese women and changes after bariatric surgery. J Reprod Med., 2009; 54: 597-602.
113. Tahtinen RM, Auvinen A, Cartwright R, Johnson TM 2nd, Tammela TL, Tikkinen KA. Smoking and bladder symptoms in women. Obstet Gynecol., 2011; 118: 643-8.
114. Cho SY, Lee SL, Kim IS, Koo DH, Kim HJ, Oh SJ. Short-term effects of systematized behavioral modification program for nocturia: a prospective study. Neurourol Urodyn, 2012; 31: 64-8.
115. Soda T, Masui K, Okuno H, Terai A, Ogawa O, Yoshimura K. Efficacy of nondrug lifestyle measures for the treatment of nocturia. J Urol., 2010; 184: 1000-4.
116. Ellsworth P, Kirshenbaum E. Update on the pharmacologic management of overactive bladder: the present and the future. Urol Nurs, 2010; 30: 29-53.

117. Corcos J, Przydacz M, Campeau L, et al. Appendix: Executive summary of CUA guideline on adult overactive bladder. Can Urol Assoc J., 2017; 11(5): E248–E49. doi: 10.5489/cuaj.4694.
118. Corcos J, Przydacz M, Campeau L, et al. CUA guideline on adult overactive bladder. Can Urol Assoc J., 2017; 11(5): E142–E73. doi: 10.5489/cuaj.4586.
119. Hsu FC, Weeks CE, Selph SS, Blazina I, Holmes RS, McDonagh MS. Updating the evidence on drugs to treat overactive bladder: A systematic review. Int Urogynecol J., 2019; 30(10): 1603–17. doi: 10.1007/s00192-019-04022-8.
120. Moga DC, Abner EL, Wu Q, Jicha GA. Bladder antimuscarinics and cognitive decline in elderly patients. Alzheimers Dement (N Y), 2017; 3(1): 139–48. doi: 10.1016/j.trci.2017.01.003.
121. Seth JH, Dowson C, Khan MS, et al. Botulinum toxin-A for the treatment of overactive bladder: UK contributions. J Clin Urol, 2013; 6(2): 77–83. doi: 10.1177/2051415812473096.
122. Sukhu T, Kennelly MJ, Kurpad R. Sacral neuromodulation in overactive bladder: A review and current perspectives. Res Rep Urol, 2016; 8: 193–99. doi: 10.2147/ RRU.S89544.
123. Willis-Gray MG, Dieter AA, Geller EJ. Evaluation and management of overactive bladder: Strategies for optimizing care. Res Rep Urol, 2016; 8: 113–22. doi: 10.2147/RRU.S93636.
124. Çetinel B, Kocjancic E, Demirdağ C. Augmentation cystoplasty in neurogenic bladder. Investig Clin Urol., 2016; 57(5): 316–23. doi: 10.4111/ icu.2016.57.5.316.
125. English SF. Update on voiding dysfunction managed with suprapubic catheterization. Transl Androl Urol, 2017; 6(2): S180–S85. doi: 10.21037/ tau.2017.04.16.
126. Srikrishna S, Robinson D, Cardozo L, Vella M. Management of overactive bladder syndrome. Postgrad Med J., 2007; 83(981): 481–86. doi: 10.1136/ pgmj.2007.
127. Armstrong, C. "AUA Releases Guideline on Diagnosis and Treatment of Overactive Bladder", *American Family Physician*, 2013; 87(11): 800-803. Available at: https://www.aafp.org/afp/2013/0601/p800.html (Accessed: 3 December 2021).
128. Finney SM, Andersson KE, Gillespie JI, Stewart LH. Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions? BJU Int., 2006; 98: 503–507.
129. Andersson KE. Bladder activation: afferent mechanisms. Urology, 2002; 59(5,1): 43–50.

130. Birder LA, de Groat WC. Mechanisms of disease: involvement of the urothelium in bladder dysfunction. Nat Clin Pract Urol., 2007; 4: 46–54.
131. Guay DR. Clinical pharmacokinetics of drugs used to treat urge incontinence. Clin Pharmacokinet, 2003; 42: 1243–1285.
132. Andersson K-E. Current concepts in the treatment of disorders of micturition. Drugs, 1988; 35: 477–494.
133. Kay G, Malhotra B, Michel MC. Central nervous system access of a new antimuscarinic drug, fesoterodine [abstract 235]. J Urol., 2009; 184.
134. Le Tu M, de Wachter S, Robert M, et al.: Initial clinical experience with selective bladder denervation for refractory overactive bladder. Neurourol Urodyn, 2019; 38(2): 644–52. 10.1002/nau.23881.
135. Robinson D, Flint R, Veit-Rubin N, et al.: Is there enough evidence to jus9fy the use of laser and other thermal therapies in female lower urinary tract dysfunc9on? Report from the ICI-RS 2019. *Neurourol Urodyn,* 2020; 39(3): S140–S147. 10.1002/ nau.24298.
136. Perino A, Cucinella G, Guglio\a G, et al.: Is vaginal frac9onal CO2 laser treatment effec9ve in improving overac9ve bladder symptoms in postmenopausal pa9ents? Preliminary results. *Eur Rev Med Pharmacol Sci.,* 2016; 20(12): 2491–7.
137. TA290: Mirabegron for trea9ng symptoms of overac9ve bladder. NICE guidance, 2013.
138. Keam SJ: Vibegron: First Global Approval. Drugs, 2018; 78(17): 1835–9. 10.1007/ s40265-018-1006-3.
139. Edmondson SD, Zhu C, Kar NF, et al.: Discovery of Vibegron: A Potent and Selec9ve β3 Adrenergic Receptor Agonist for the Treatment of Overac9ve Bladder. J Med Chem., 2016; 59(2): 609–23. 10.1021/acs.jmedchem.5b01372.
140. Bragg R, Hebel D, Vouri SM, et al.: Mirabegron: a Beta-3 agonist for overac9ve bladder. Consult Pharm., 2014; 29(12): 823–37. 10.4140/TCP.n.2014.823.
141. Efficacy of Daily Low-dose Tadalafil for Treating Overactive Bladder: Results of a Randomized, Double-blind, Placebo-controlled Trial. Chen H, Wang F, Yu Z, Zhang Y, Liu C, Dai S, Chen B, Lv JUrology, Feb., 2017; 100: 59-64.
142. Posterior tibial nerve stimulation for overactive bladder-techniques and efficacy. Bhide AA, Tailor V, Fernando R, Khullar V, Digesu GA Int Urogynecol J., May, 2020; 31(5): 865-870.
143. Van Breda HMK, Martens FMJ, Tromp J, et al.: A New Implanted Posterior Tibial Nerve Stimulator for the Treatment of Overactive Bladder Syndrome: 3-Month Results

of a Novel Therapy at a Single Center. *J Urol.*, 2017; 198(1): 205–10. 10.1016/j.juro.2017.01.078.

144. Heesakkers JPFA, Digesu GA, van Breda J, et al.: A novel leadless, miniature implantable Tibial Nerve Neuromodulation System for the management of overactive bladder complaints. *Neurourol Urodyn*, 2018; 37(3): 1060–7. 10.1002/ nau.23401.
145. Dmochowski RR, van Kerrebroeck P, Digesu GA, et al. : PD31-02 LONGTERM RESULTS OF SAFETY, EFFICACY, QUALITY OF LIFE AND SATISFACTION OF PATIENTS TREATED FOR REFRACTORY OAB USING AN IMPLANTABLE TIBIAL NEUROSTIMULATION SYSTEM: RENOVA ISTIM™ SYSTEM. *J Urol.*, 2019; 201: e565–e566. 10.1097/01.JU.0000556189.77639.e5.
146. Marcelissen TAT, Leong RK, de Bie RA, et al.: Long-term results of sacral neuromodulation with the tined lead procedure. *J Urol.*, 2010; 184(5): 1997–2000. 10.1016/j.juro.2010.06.142 [PubMed] [CrossRef] [Google Scholar]
147. MRI guidelines for InterStim Therapy Neurostimulation Systems. 1st ed. Medtronic, 2017. Reference Source [Google Scholar].
148. The Axonics Sacral Neuromodulation System: Product Overview and Technical Deep-Dive., 2016. [Google Scholar].
149. Cohn JA, Kowalik CG, Kaufman MR, et al. : Evaluation of the axonics modulation technologies sacral neuromodulation system for the treatment of urinary and fecal dysfunction. *Expert Rev Med Devices*, 2016; 14(1): 3–14. 10.1080/17434440.2017.1268913.
150. Chancellor MB, Staskin DR, Kay GG, Sandage BW, Oefelein MG, Tsao JW. Blood-brain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladder. Drugs Aging, 2012; 29: 259-73.
151. Zinner N. Darifenacin: a muscarinic M3-selective receptor antagonist for the treatment of overactive bladder. Expert Opin Pharmacother, 2007; 8: 511-23.
152. Ney P, Pandita RK, Newgreen DT, Breidenbach A, Stöhr T, Andersson KE. Pharmacological characterization of a novel investigational antimuscarinic drug, fesoterodine, in vitro and in vivo. BJU Int., 2008; 101: 103642.
153. Malhotra B, Gandelman K, Sachse R, Wood N, Michel MC. The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine. Curr Med Chem., 2009; 16: 4481-9.
154. Chapple CR, Nazir J, Hakimi Z, Bowditch S, Fatoye F, Guelfucci F, et al. Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with

Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice. Eur Urol., 2017; 72: 389-99.

155. Wagg A, Franks B, Ramos B, Berner T. Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: Early experience in Canada. Can Urol Assoc J., 2015; 9: 343-50.
156. Lozano-Ortega G, Ng DB, Szabo SM, Deighton AM, Riveros B, Guttschow A, et al. Management of Patients with Overactive Bladder in Brazil: A. Retrospective Observational Study Using Data From the Brazilian Public Health System. Adv Ther., 2020; 37: 2344-55.
157. Ju R, Garrett J, Wu JM. Anticholinergic medication use for female overactive bladder in the ambulatory setting in the United States. Int Urogynecol J., 2014; 25: 479-84.
158. Andersson KE, Chapple CR. Oxybutynin and the overactive bladder. World J Urol., 2001; 19: 319-23.
159. Aderson GF, Fredericks CM. Characterization of the oxybutynin antagonism of drug-induced spasms in detrusor. Pharmacology, 1977; 15: 31-9.
160. Waldeck K, Larsson B, Andersson KE. Comparison of oxybutynin and its active metabolite, N-desethyl-oxybutynin, in the human detrusor and parotid gland. J Urol., 1997; 157: 1093-7.
161. Staskin DR, Dmochowski RR, Sand PK, Macdiarmid SA, Caramelli KE, Thomas H, et al. Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study. J Urol., 2009; 181: 1764-72.
162. Dmochowski RR, Davila GW, Zinner NR, Gittelman MC, Saltzstein DR, Lyttle S, et al. Transdermal Oxybutynin Study Group. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol., 2002; 168: 580-6.
163. Appell RA, Sand P, Dmochowski R, Anderson R, Zinner N, Lama D, et al. Overactive Bladder: Judging Effective Control and Treatment Study Group. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc., 2001; 76: 358-63.
164. Dmochowski RR, Sand PK, Zinner NR, Gittelman MC, Davila GW, Sanders SW, et al. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology, 2003; 62: 237-42.

165. Haruno A. Inhibitory effects of propiverine hydrochloride on the agonistinduced or spontaneous contractions of various isolated muscle preparations. Arzneimittelforschung, 1992; 42: 815-7.
166. Wuest M, Witte LP, Michel-Reher MB, Propping S, Braeter M, Strugala GJ, et al. The muscarinic receptor antagonist propiverine exhibits α(1)-adrenoceptor antagonism in human prostate and porcine trigonum. World J Urol, 2011; 29: 149-55.
167. Staskin D, Kay G, Tannenbaum C, Goldman HB, Bhashi K, Ling J, et al. Trospium chloride is undetectable in the older human central nervous system. J Am Geriatr Soc., 2010; 58: 1618-9.
168. Todorova A, Vonderheid-Guth B, Dimpfel W. Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol, 2001; 41: 636-44.
169. Staskin D, Kay G, Tannenbaum C, Goldman HB, Bhashi K, Ling J, et al. Trospium chloride has no effect on memory testing and is assay undetectable in the central nervous system of older patients with overactive bladder. Int J Clin Pract, 2010; 64: 1294-300.
170. Rovner ES. Trospium chloride in the management of overactive bladder. Drugs, 2004; 64: 2433-46.
171. Kim Y, Yoshimura N, Masuda H, De Miguel F, Chancellor MB. Intravesical instillation of human urine after oral administration of trospium, tolterodine and oxybutynin in a rat model of detrusor overactivity. BJU Int., 2006; 97: 400-3.
172. Dmochowski RR, Starkman JS, Davila GW. Transdermal drug delivery treatment for overactive bladder. Int Braz J Urol., 2006; 32: 513-20.
173. Cohn JA, Brown ET, Reynolds WS, Kaufman MR, Milam DF, Dmochowski RR. An update on the use of transdermal oxybutynin in the management of overactive bladder disorder. Ther Adv Urol., 2016; 8: 83-90.
174. Davila GW, Starkman JS, Dmochowski RR. Transdermal oxybutynin for overactive bladder. Urol Clin North Am., 2006; 33: 455-63, viii.
175. Davila GW, Daugherty CA, Sanders SW; Transdermal Oxybutynin Study Group. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol., 2001; 166: 140-5.

176. Dmochowski RR, Nitti V, Staskin D, Luber K, Appell R, Davila GW. Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials. World J Urol, 2005; 23: 26370.
177. Yamaguchi O. Latest treatment for lower urinary tract dysfunction: therapeutic agents and mechanism of action. Int J Urol., 2013; 20: 28-39.
178. Coelho A, Antunes-Lopes T, Gillespie J, Cruz F. Beta- 3 adrenergic receptor is expressed in acetylcholine-containing nerve fibers of the human urinary bladder: An immunohistochemical study. Neurourol Urodyn, 2017; 36: 1972-80.
179. Rovner E, Chai TC, Jacobs S, Christ G, Andersson KE, Efros M, et al. Evaluating the safety and potential activity of URO- 902 (hMaxi-K) gene transfer by intravesical instillation or direct injection into the bladder wall in female participants with idiopathic (non-neurogenic) overactive bladder syndrome and detrusor overactivity from two double-blind, imbalanced, placebo-controlled randomized phase 1 trials. Neurourol Urodyn, 2020; 39: 744-53.
180. Fry CH, Chakrabarty B, Hashitani H, Andersson KE, McCloskey K, Jabr RI, et al. New targets for overactive bladder-ICI-RS 2109. Neurourol Urodyn, 2020; 39(3): S113-S121.
181. Cockayne DA, Hamilton SG, Zhu QM, Dunn PM, Zhong Y, Novakovic S, et al. Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X3deficient mice. Nature., 2000; 407: 1011-5.
182. Moldwin R, Kitt M, Mangel J, et al. A phase 2 study in women with interstitial cystitis/bladder pain syndrome (IC/BPS) of the novel P2X3 antagonist AF-219. [abstract No. 23]. 45th International Continence Society (ICS) Annual Meeting; 2015; Montreal, Canada.
183. Mukerji G, Yiangou Y, Agarwal SK, Anand P. Increased cannabinoid receptor 1immunoreactive nerve fibers in overactive and painful bladder disorders and their correlation with symptoms. Urology, 2010; 75: 1514.e15-20.
184. Jaggar SI, Hasnie FS, Sellaturay S, Rice AS. The anti- hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain., 1998; 76: 189-99.
185. Farquhar-Smith WP, Jaggar SI, Rice AS. Attenuation of nerve growth factorinduced visceral hyperalgesia via cannabinoid CB(1) and CB(2)-like receptors. Pain., 2002; 97: 11-21.

186. Walczak JS, Price TJ, Cervero F. Cannabinoid CB1 receptors are expressed in the mouse urinary bladder and their activation modulates afferent bladder activity. Neuroscience, 2009; 159: 1154-63.
187. Bakali E, Mbaki Y, Lambert DG, Elliott RA, Mason R, Tincello DG. Effects of cannabinoid receptor activation by CP55,940 on normal bladder function and irritation-induced bladder overactivity in non-awake anaesthetised rats. Int Urogynecol J., 2016; 27: 1393-400.
188. Maniscalco GT, Aponte R, Bruzzese D, Guarcello G, Manzo V, Napolitano M, et al. THC/CBD oromucosal spray in patients with multiple sclerosis overactive bladder: a pilot prospective study. Neurol Sci., 2018; 39: 97-102.
189. Merrill L, Gonzalez EJ, Girard BM, Vizzard MA. Receptors, channels, and signalling in the urothelial sensory system in the bladder. Nat Rev Urol., 2016; 13: 193-204.
190. Andersson KE. TRP Channels as Lower Urinary Tract Sensory Targets. Med Sci (Basel)., 2019; 7: 67.
191. Brown W, Leff RL, Griffin A, Hossack S, Aubray R, Walker P, et al. Safety, Pharmacokinetics, and Pharmacodynamics Study in Healthy Subjects of Oral NEO6860, a Modality Selective Transient Receptor Potential Vanilloid Subtype 1 Antagonist. J Pain., 2017; 18:726-38. Erratum in: J Pain., 2017; 18: 1150-1151.